Epigenomics AG (Frankfurt, Prime Standard: ECX) has entered into an R&D collaboration with Centocor Inc., a US-based, biomedicines company, to identify and analyze potential biomarkers for use in Centocor’s oncology program. Under the agreement, Epigenomics will use its proprietary Differential Methylation Hybridization (DMH) microarray platform to perform genome-wide DNA methylation profiling study on samples provided by Centocor. The goal of the collaboration is to identify candidate DNA methylation biomarkers that may support drug development and could ultimately be used for selecting patients that have a higher chance of benefiting from a drug candidate under development at Centocor. Financial details were not disclosed.
